Advertisement

Radical Cystectomy

  • Hyeong Dong Yuk
Chapter

Abstract

Bladder cancer is the fourth most common cancer in men in the United States. About 60,000 people develop each year. Bladder cancer is the eighth leading cause of cancer deaths in the United States. About 12,000 people die each year from bladder cancer. In 2017, there were 79,030 cases of bladder cancer, and 16,870 patients died of bladder cancer in the United States. At the initial diagnosis, 20–30% are diagnosed with muscle-invasive bladder cancer (MIBC). The survival rate of the MIBC patients is significantly lower than that of patients with non-muscle-invasive bladder cancer (NMIBC). Therefore, various and complex treatments are needed to improve the survival rate. In the non-metastatic MIBC patients, surgery is the standard treatment, and various treatments such as chemotherapy, radiotherapy, and bladder preservation are being performed.

In this chapter, we will discuss the evaluation and treatment of MIBC patients.

Keywords

Muscle-invasive bladder cancer Radical cystectomy Urinary diversion Lymph node dissection Radiotherapy Chemotherapy Multimodal therapy 

References

  1. 1.
    Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol. 1987;138:1162–3.PubMedCrossRefGoogle Scholar
  2. 2.
    Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001;19:89–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Solsona E, Iborra I, Collado A, Rubio-Briones J, Casanova J, Calatrava A. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol. 2010;184:475–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Balar AV, Milowsky MI. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough? Cancer. 2015;121:179–87.PubMedCrossRefGoogle Scholar
  5. 5.
    Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2009;55:348–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001;19:4005–13.PubMedCrossRefGoogle Scholar
  7. 7.
    Teramukai S, Nishiyama H, Matsui Y, Ogawa O, Fukushima M. Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res. 2006;12:139–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999;354:533–40.Google Scholar
  9. 9.
    Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996;155:1903–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45:297–303.PubMedCrossRefGoogle Scholar
  12. 12.
    Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol. 1991;67:608–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Bassi P, et al. Neo-adjuvant M-VAC of invasive bladder cancer: G.U.O.N.E. multicenter phase III trial. Eur Urol. 1998;33:142.Google Scholar
  14. 14.
    Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, Flores N, Roncero CR, Portillo JA, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol. 1995;153:964–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Sengelov L, von der Maase H, Lundbeck F, Barlebo H, Colstrup H, Engelholm SA, et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol. 2002;41:447–56.PubMedCrossRefGoogle Scholar
  16. 16.
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202–5. discussion 5–6.CrossRefGoogle Scholar
  17. 17.
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927–34.CrossRefGoogle Scholar
  18. 18.
    Winquist E, Kirchner TS, Segal R, Chin J, Lukka H, Genitourinary Cancer Disease Site Group CCOPiE-bCPGI. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004;171:561–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN guidelines insights: bladder cancer, version 2.2016. J Natl Compr Cancer Netw. 2016;14:1213–24.CrossRefGoogle Scholar
  20. 20.
    Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462–75.PubMedCrossRefGoogle Scholar
  21. 21.
    Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638–46.PubMedCrossRefGoogle Scholar
  22. 22.
    McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial Cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol. 2016;69:855–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Dash A, Pettus JA, Herr HW, Bochner BH, Dalbagni G, Donat SM, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113:2471–7.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171–7.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.Google Scholar
  26. 26.
    Harada K, Sakai I, Hara I, Eto H, Miyake H. Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy. Int J Urol. 2005;12:250–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Herr HW. A proposed simplified staging system of invasive bladder tumors. Urol Int. 1993;50:17–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Quek ML, Stein JP, Nichols PW, Cai J, Miranda G, Groshen S, et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol. 2005;174:103–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Soave A, Schmidt S, Dahlem R, Minner S, Engel O, Kluth LA, et al. Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol. 2015;33(1):21.e1–9.CrossRefGoogle Scholar
  30. 30.
    Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115:4104–9.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Haleblian GE, Skinner EC, Dickinson MG, Lieskovsky G, Boyd SD, Skinner DG. Hydronephrosis as a prognostic indicator in bladder cancer patients. J Urol. 1998;160:2011–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Bartsch GC, Kuefer R, Gschwend JE, De Petriconi R, Hautmann RE, Volkmer BG. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol. 2007;51:690–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel DE, et al. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol. 2010;34:1367–76.PubMedCrossRefGoogle Scholar
  34. 34.
    Shah RB, Montgomery JS, Montie JE, Kunju LP. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol. 2013;31:1650–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013;64:307–13.PubMedCrossRefGoogle Scholar
  36. 36.
    Keck B, Stoehr R, Wach S, Rogler A, Hofstaedter F, Lehmann J, et al. The plasmacytoid carcinoma of the bladder-rare variant of aggressive urothelial carcinoma. Int J Cancer. 2011;129:346–54.PubMedCrossRefGoogle Scholar
  37. 37.
    Ricardo-Gonzalez RR, Nguyen M, Gokden N, Sangoi AR, Presti JC, McKenney JK. Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for Intraperitoneal spread. J Urol. 2012;187:852–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145:459–64. discussion 64–7.PubMedCrossRefGoogle Scholar
  39. 39.
    de Wit R, European Organization for Research and Treatment. Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer. 2003;97:2120–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012;23:695–700.PubMedCrossRefGoogle Scholar
  41. 41.
    Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:76–86.PubMedCrossRefGoogle Scholar
  42. 42.
    Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48:189–99. discussion 99–201.CrossRefGoogle Scholar
  43. 43.
    Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Ogden S, von Eschenbach A, et al. Adjuvant chemotherapy of bladder cancer: a preliminary report. J Urol. 1988;139:1207–11.PubMedCrossRefGoogle Scholar
  44. 44.
    Bono AV, Benvenuti C, Reali L, Pozzi E, Gibba A, Cosciani-Cunico S, et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res. 1989;303:533–40.PubMedGoogle Scholar
  45. 45.
    Stockle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thuroff JW, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 1992;148:302–6. discussion 6–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol. 1994;152:81–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996;155:495–9. discussion 9–500.PubMedCrossRefGoogle Scholar
  48. 48.
    Otto T, Goebell PJ, Rubben H. Perioperative chemotherapy in advanced bladder cancer - part II: adjuvant treatment. Onkologie. 2003;26:484–8.PubMedGoogle Scholar
  49. 49.
    Lehmann J, Franzaring L, Thuroff J, Wellek S, Stockle M. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int. 2006;97:42–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Onco. 2010:28(18_suppl):LBA4518.CrossRefGoogle Scholar
  51. 51.
    Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011;29:3443–9.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Zaghloul MS, Christodouleas JP, Smith A, Abdallah A, William H, Khaled HM, et al. Adjuvant Sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy: a randomized phase 2 trial. JAMA Surg. 2018;153:e174591.PubMedCrossRefGoogle Scholar
  53. 53.
    Zaghloul MS, Awwad HK, Akoush HH, Omar S, Soliman O, el Attar I. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992;23:511–7.PubMedCrossRefGoogle Scholar
  54. 54.
    El-Monim HA, El-Baradie MM, Younis A, Ragab Y, Labib A, El-Attar I. A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer. Urol Oncol. 2013;31:359–65.PubMedCrossRefGoogle Scholar
  55. 55.
    Moschini M, Sharma V, Dell’oglio P, Cucchiara V, Gandaglia G, Cantiello F, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2016;117:604–10.PubMedCrossRefGoogle Scholar
  56. 56.
    van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011;60:493–500.PubMedCrossRefGoogle Scholar
  57. 57.
    Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010;57:300–9.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol. 2009;27:347–51.PubMedCrossRefGoogle Scholar
  59. 59.
    Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690–6.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Hiraoka M, Sung S, Davis J, Kim D. Faculty and resident perceptions regarding overnight student call during the third year OB/GYN clerkship. Hawaii Med J. 2011;70:189–92.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163:1693–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Tritschler S, Mosler C, Tilki D, Buchner A, Stief C, Graser A. Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. Urology. 2012;79:1317–21.PubMedCrossRefGoogle Scholar
  64. 64.
    Rajesh A, Sokhi HK, Fung R, Mulcahy KA, Bankart MJ. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol. 2011;66:1140–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Tekes A, Kamel I, Imam K, Szarf G, Schoenberg M, Nasir K, et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol. 2005;184:121–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Bouchelouche K, Turkbey B, Choyke PL. PET/CT and MRI in bladder cancer. J Cancer Sci Ther. 2012;S14(1):7692.PubMedGoogle Scholar
  67. 67.
    Tyson MD, Castle EP, Humphreys MR, Andrews PE. Venous thromboembolism after urological surgery. J Urol. 2014;192:793–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Violette PD, Cartwright R, Briel M, Tikkinen KA, Guyatt GH. Guideline of guidelines: thromboprophylaxis for urological surgery. BJU Int. 2016;118:351–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4.PubMedCrossRefGoogle Scholar
  70. 70.
    Zareba P, Patterson L, Pandya R, Margel D, Hotte SJ, Mukherjee SD, et al. Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy. Urol Oncol. 2014;32:975–80.PubMedCrossRefGoogle Scholar
  71. 71.
    Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, et al. Incidence, characteristics and implications of thromboembolic events in patients with muscle invasive urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy. J Urol. 2016;196:1627–33.PubMedCrossRefGoogle Scholar
  72. 72.
    Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e227S–e77S.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Venclauskas L, Llau JV, Jenny JY, Kjaersgaard-Andersen P, Jans O, Force EVGT. European guidelines on perioperative venous thromboembolism prophylaxis: day surgery and fast-track surgery. Eur J Anaesthesiol. 2018;35:134–8.PubMedGoogle Scholar
  74. 74.
    Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel, et al. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:7S–47S.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    VanDlac AA, Cowan NG, Chen Y, Anderson RE, Conlin MJ, La Rochelle JC, et al. Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis. J Urol. 2014;191:943–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect. 2013;14:73–156.CrossRefGoogle Scholar
  77. 77.
    Dunglison NT, Gardiner RA. Continent bladder stoma. World J Urol. 2003;21:123–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Kluth LA, Xylinas E, Rieken M, El Ghouayel M, Sun M, Karakiewicz PI, et al. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2014;113:393–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Linder BJ, Frank I, Cheville JC, Tollefson MK, Thompson RH, Tarrell RF, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 2013;63:839–45.PubMedCrossRefGoogle Scholar
  80. 80.
    Aning J, Dunn J, Daugherty M, Mason R, Pocock R, Ridler B, et al. Towards bloodless cystectomy: a 10-year experience of intra-operative cell salvage during radical cystectomy. BJU Int. 2012;110:E608–13.PubMedCrossRefGoogle Scholar
  81. 81.
    Waters JH, Yazer M, Chen YF, Kloke J. Blood salvage and cancer surgery: a meta-analysis of available studies. Transfusion. 2012;52:2167–73.PubMedCrossRefGoogle Scholar
  82. 82.
    Mattei A, Birkhaeuser FD, Baermann C, Warncke SH, Studer UE. To stent or not to stent perioperatively the ureteroileal anastomosis of ileal orthotopic bladder substitutes and ileal conduits? Results of a prospective randomized trial. J Urol. 2008;179:582–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Adamakis I, Tyritzis SI, Koutalellis G, Tokas T, Stravodimos KG, Mitropoulos D, et al. Early removal of nasogastric tube is beneficial for patients undergoing radical cystectomy with urinary diversion. Int Braz J Urol. 2011;37:42–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Cerantola Y, Valerio M, Persson B, Jichlinski P, Ljungqvist O, Hubner M, et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: enhanced recovery after surgery (ERAS(R)) society recommendations. Clin Nutr. 2013;32:879–87.PubMedCrossRefGoogle Scholar
  85. 85.
    Danna BJ, Wood EL, Baack Kukreja JE, Shah JB. The future of enhanced recovery for radical cystectomy: current evidence, barriers to adoption, and the next steps. Urology. 2016;96:62–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Holte K, Nielsen KG, Madsen JL, Kehlet H. Physiologic effects of bowel preparation. Dis Colon Rectum. 2004;47:1397–402.PubMedCrossRefGoogle Scholar
  87. 87.
    Guenaga KF, Matos D, Wille-Jorgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev. 2011;9:CD001544.Google Scholar
  88. 88.
    Shafii M, Murphy DM, Donovan MG, Hickey DP. Is mechanical bowel preparation necessary in patients undergoing cystectomy and urinary diversion? BJU Int. 2002;89:879–81.PubMedCrossRefGoogle Scholar
  89. 89.
    Xu R, Zhao X, Zhong Z, Zhang L. No advantage is gained by preoperative bowel preparation in radical cystectomy and ileal conduit: a randomized controlled trial of 86 patients. Int Urol Nephrol. 2010;42:947–50.PubMedCrossRefGoogle Scholar
  90. 90.
    Smith I, Kranke P, Murat I, Smith A, O’Sullivan G, Soreide E, et al. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2011;28:556–69.PubMedCrossRefGoogle Scholar
  91. 91.
    Ljungqvist O, Jonathan E. Rhoads lecture 2011: insulin resistance and enhanced recovery after surgery. JPEN J Parenter Enteral Nutr. 2012;36:389–98.PubMedCrossRefGoogle Scholar
  92. 92.
    Yuill KA, Richardson RA, Davidson HI, Garden OJ, Parks RW. The administration of an oral carbohydrate-containing fluid prior to major elective upper-gastrointestinal surgery preserves skeletal muscle mass postoperatively--a randomised clinical trial. Clin Nutr. 2005;24:32–7.PubMedCrossRefGoogle Scholar
  93. 93.
    Nygren J. The metabolic effects of fasting and surgery. Best Pract Res Clin Anaesthesiol. 2006;20:429–38.PubMedCrossRefGoogle Scholar
  94. 94.
    Awad S, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of randomised controlled trials on preoperative oral carbohydrate treatment in elective surgery. Clin Nutr. 2013;32:34–44.PubMedCrossRefGoogle Scholar
  95. 95.
    Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, et al. Guidelines for perioperative care in elective colonic surgery: enhanced recovery after surgery (ERAS(R)) society recommendations. World J Surg. 2013;37:259–84.PubMedCrossRefGoogle Scholar
  96. 96.
    Carli F, Charlebois P, Stein B, Feldman L, Zavorsky G, Kim DJ, et al. Randomized clinical trial of prehabilitation in colorectal surgery. Br J Surg. 2010;97:1187–97.PubMedCrossRefGoogle Scholar
  97. 97.
    Vaughan-Shaw PG, Fecher IC, Harris S, Knight JS. A meta-analysis of the effectiveness of the opioid receptor antagonist alvimopan in reducing hospital length of stay and time to GI recovery in patients enrolled in a standardized accelerated recovery program after abdominal surgery. Dis Colon Rectum. 2012;55:611–20.PubMedCrossRefGoogle Scholar
  98. 98.
    Gianotti L, Nespoli L, Torselli L, Panelli M, Nespoli A. Safety, feasibility, and tolerance of early oral feeding after colorectal resection outside an enhanced recovery after surgery (ERAS) program. Int J Color Dis. 2011;26:747–53.CrossRefGoogle Scholar
  99. 99.
    Schroeder D, Gillanders L, Mahr K, Hill GL. Effects of immediate postoperative enteral nutrition on body composition, muscle function, and wound healing. JPEN J Parenter Enteral Nutr. 1991;15:376–83.PubMedCrossRefGoogle Scholar
  100. 100.
    Pang KH, Groves R, Venugopal S, Noon AP, Catto JW. Prospective implementation of enhanced recovery after surgery protocols to radical cystectomy. Eur Urol. 2018;73(3):363–71.CrossRefGoogle Scholar
  101. 101.
    Harper CM, Lyles YM. Physiology and complications of bed rest. J Am Geriatr Soc. 1988;36:1047–54.PubMedCrossRefGoogle Scholar
  102. 102.
    Horenblas S, Meinhardt W, Ijzerman W, Moonen LF. Sexuality preserving cystectomy and neobladder: initial results. J Urol. 2001;166:837–40.PubMedCrossRefGoogle Scholar
  103. 103.
    Vallancien G, Abou El Fettouh H, Cathelineau X, Baumert H, Fromont G, Guillonneau B. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol. 2002;168:2413–7.PubMedCrossRefGoogle Scholar
  104. 104.
    Tal R, Baniel J. Sexual function-preserving cystectomy. Urology. 2005;66:235–41.PubMedCrossRefGoogle Scholar
  105. 105.
    Terrone C, Cracco C, Scarpa RM, Rossetti SR. Supra-ampullar cystectomy with preservation of sexual function and ileal orthotopic reservoir for bladder tumor: twenty years of experience. Eur Urol. 2004;46:264–9. discussion 9–70.PubMedCrossRefGoogle Scholar
  106. 106.
    Spitz A, Stein JP, Lieskovsky G, Skinner DG. Orthotopic urinary diversion with preservation of erectile and ejaculatory function in men requiring radical cystectomy for nonurothelial malignancy: a new technique. J Urol. 1999;161:1761–4.PubMedCrossRefGoogle Scholar
  107. 107.
    Satkunasivam R, Hu B, Daneshmand S. Is frozen section analysis of ureteral margins at time of radical cystectomy useful? Curr Urol Rep. 2015;16:38.PubMedCrossRefGoogle Scholar
  108. 108.
    Raj GV, Tal R, Vickers A, Bochner BH, Serio A, Donat SM, et al. Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. Cancer. 2006;107:2167–72.PubMedCrossRefGoogle Scholar
  109. 109.
    Satkunasivam R, Hu B, Metcalfe C, Ghodoussipour SB, Aron M, Cai J, et al. Utility and significance of ureteric frozen section analysis during radical cystectomy. BJU Int. 2016;117:463–8.PubMedCrossRefGoogle Scholar
  110. 110.
    Gakis G, Schilling D, Perner S, Schwentner C, Sievert KD, Stenzl A. Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis. World J Urol. 2011;29:451–6.PubMedCrossRefGoogle Scholar
  111. 111.
    Johnson DE, Wishnow KI, Tenney D. Are frozen-section examinations of ureteral margins required for all patients undergoing radical cystectomy for bladder cancer? Urology. 1989;33:451–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Schoenberg MP, Carter HB, Epstein JI. Ureteral frozen section analysis during cystectomy: a reassessment. J Urol. 1996;155:1218–20.PubMedCrossRefGoogle Scholar
  113. 113.
    Silver DA, Stroumbakis N, Russo P, Fair WR, Herr HW. Ureteral carcinoma in situ at radical cystectomy: does the margin matter? J Urol. 1997;158:768–71.PubMedCrossRefGoogle Scholar
  114. 114.
    Tollefson MK, Blute ML, Farmer SA, Frank I. Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol. 2010;183:81–6.PubMedCrossRefGoogle Scholar
  115. 115.
    Al Hussein Al Awamlh B, Wang LC, Nguyen DP, Rieken M, Lee RK, Lee DJ, et al. Is continent cutaneous urinary diversion a suitable alternative to orthotopic bladder substitute and ileal conduit after cystectomy? BJU Int. 2015;116:805–14.PubMedCrossRefGoogle Scholar
  116. 116.
    Kassouf W, Hautmann RE, Bochner BH, Lerner SP, Colombo R, Zlotta A, et al. A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? Eur Urol. 2010;58:374–83.PubMedCrossRefGoogle Scholar
  117. 117.
    Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol. 2003;169:105–9.PubMedCrossRefGoogle Scholar
  118. 118.
    Nayak JG, Gore JL, Holt SK, Wright JL, Mossanen M, Dash A. Patient-centered risk stratification of disposition outcomes following radical cystectomy. Urol Oncol. 2016;34:235.e17–23.CrossRefGoogle Scholar
  119. 119.
    Zaid HB, Kaffenberger SD, Chang SS. Improvements in safety and recovery following cystectomy: reassessing the role of pre-operative bowel preparation and interventions to speed return of post-operative bowel function. Curr Urol Rep. 2013;14:78–83.PubMedCrossRefGoogle Scholar
  120. 120.
    Ardelt PU, Woodhouse CR, Riedmiller H, Gerharz EW. The efferent segment in continent cutaneous urinary diversion: a comprehensive review of the literature. BJU Int. 2012;109:288–97.PubMedCrossRefGoogle Scholar
  121. 121.
    Van der Aa F, Joniau S, Van Den Branden M, Van Poppel H. Metabolic changes after urinary diversion. Adv Urol. 2011;2011:764325.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Shimko MS, Tollefson MK, Umbreit EC, Farmer SA, Blute ML, Frank I. Long-term complications of conduit urinary diversion. J Urol. 2011;185:562–7.PubMedCrossRefGoogle Scholar
  123. 123.
    Koch MO, McDougal WS, Hall MC, Hill DE, Braren HV, Donofrio MN. Long-term metabolic effects of urinary diversion: a comparison of myelomeningocele patients managed by clean intermittent catheterization and urinary diversion. J Urol. 1992;147:1343–7.PubMedCrossRefGoogle Scholar
  124. 124.
    McDougal WS. Metabolic complications of urinary intestinal diversion. J Urol. 1992;147:1199–208.PubMedCrossRefGoogle Scholar
  125. 125.
    Stein R, Rubenwolf P. Metabolic consequences after urinary diversion. Front Pediatr. 2014;2:15.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Vasdev N, Moon A, Thorpe AC. Metabolic complications of urinary intestinal diversion. Indian J Urol. 2013;29:310–5.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    World Health Organization Consensus Conference on Bladder Cancer, Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W, et al. Urinary diversion. Urology. 2007;69:17–49.Google Scholar
  128. 128.
    Hautmann RE, Volkmer BG, Schumacher MC, Gschwend JE, Studer UE. Long-term results of standard procedures in urology: the ileal neobladder. World J Urol. 2006;24:305–14.PubMedCrossRefGoogle Scholar
  129. 129.
    Studer UE, Varol C, Danuser H. Orthotopic ileal neobladder. BJU Int. 2004;93:183–93.PubMedCrossRefGoogle Scholar
  130. 130.
    Holzbeierlein JM, Lopez-Corona E, Bochner BH, Herr HW, Donat SM, Russo P, et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol. 2004;172:878–81.PubMedCrossRefGoogle Scholar
  131. 131.
    Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006;175:2058–62.PubMedCrossRefGoogle Scholar
  132. 132.
    Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RL Jr. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology. 2008;72:613–6.PubMedCrossRefGoogle Scholar
  133. 133.
    Capitanio U, Isbarn H, Shariat SF, Jeldres C, Zini L, Saad F, et al. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology. 2009;74:858–64.PubMedCrossRefGoogle Scholar
  134. 134.
    Fahmy N, Aprikian A, Tanguay S, Mahmud SM, Al-Otaibi M, Jeyaganth S, et al. Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol. 2010;28:419–23.PubMedCrossRefGoogle Scholar
  135. 135.
    Knoedler JJ, Boorjian SA, Kim SP, Weight CJ, Thapa P, Tarrell RF, et al. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol. 2012;188:1115–9.PubMedCrossRefGoogle Scholar
  136. 136.
    Golombos DM, O’Malley P, Lewicki P, Stone BV, Scherr DS. Robot-assisted partial cystectomy: perioperative outcomes and early oncological efficacy. BJU Int. 2017;119:128–34.PubMedCrossRefGoogle Scholar
  137. 137.
    Cooper JF, Leadbetter WF, Chute R. The thoracoabdominal approach for retroperitoneal gland dissection: its application to testis tumors. 1950. J Urol. 2002;167:920–6. discussion 7.PubMedCrossRefGoogle Scholar
  138. 138.
    Smith JA Jr, Whitmore WF Jr. Regional lymph node metastasis from bladder cancer. J Urol. 1981;126:591–3.PubMedCrossRefGoogle Scholar
  139. 139.
    Herr H, Lee C, Chang S, Lerner S, Bladder Cancer Collaborative G. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol. 2004;171:1823–8. discussion 7–8.PubMedCrossRefGoogle Scholar
  140. 140.
    Ozen H, Ugurlu O, Baltaci S, Adsan O, Aslan G, Can C, et al. Extended pelvic lymph node dissection: before or after radical cystectomy? A multicenter study of the Turkish society of urooncology. Korean J Urol. 2012;53:451–6.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Larcher A, Sun M, Schiffmann J, Tian Z, Shariat SF, McCormack M, et al. Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer. Eur J Surg Oncol. 2015;41:353–60.PubMedCrossRefGoogle Scholar
  142. 142.
    Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol. 1998;160:2015–9. discussion 20.PubMedCrossRefGoogle Scholar
  143. 143.
    Simone G, Papalia R, Ferriero M, Guaglianone S, Castelli E, Collura D, et al. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol. 2013;20:390–7.PubMedCrossRefGoogle Scholar
  144. 144.
    Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 2008;179:873–8. discussion 8.PubMedCrossRefGoogle Scholar
  145. 145.
    Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol. 2003;170:35–41.CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol. 2003;169:943–5.PubMedCrossRefGoogle Scholar
  147. 147.
    Ku JH, Kang M, Kim HS, Jeong CW, Kwak C, Kim HH. Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis. BMC Cancer. 2015;15:447.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer. 2008;112:2401–8.PubMedCrossRefGoogle Scholar
  149. 149.
    Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, et al. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013;31:480–6.PubMedCrossRefGoogle Scholar
  150. 150.
    Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, et al. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol. 2012;187:845–51.PubMedCrossRefGoogle Scholar
  151. 151.
    Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol. 2005;23:2358–65.PubMedCrossRefGoogle Scholar
  152. 152.
    Masson-Lecomte A, Vordos D, Hoznek A, Yiou R, Allory Y, Abbou CC, et al. External validation of extranodal extension and lymph node density as predictors of survival in node-positive bladder cancer after radical cystectomy. Ann Surg Oncol. 2013;20:1389–94.PubMedCrossRefGoogle Scholar
  153. 153.
    Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, et al. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer. 2006;107:1491–5.PubMedCrossRefGoogle Scholar
  154. 154.
    Kim SH, Yu A, Jung JH, Lee YJ, Lee ES. Incidence and risk factors of 30-day early and 90-day late morbidity and mortality of radical cystectomy during a 13-year follow-up: a comparative propensity-score matched analysis of complications between neobladder and ileal conduit. Jpn J Clin Oncol. 2014;44:677–85.PubMedCrossRefGoogle Scholar
  155. 155.
    Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164–74.PubMedCrossRefGoogle Scholar
  156. 156.
    Gupta H, Srivastava A, Menon GR, Agrawal CS, Chumber S, Kumar S. Comparison of interrupted versus continuous closure in abdominal wound repair: a meta-analysis of 23 trials. Asian J Surg. 2008;31:104–14.PubMedCrossRefGoogle Scholar
  157. 157.
    Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, et al. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol. 2014;66:156–63.PubMedCrossRefGoogle Scholar
  158. 158.
    Schiavina R, Borghesi M, Guidi M, Vagnoni V, Zukerman Z, Pultrone C, et al. Perioperative complications and mortality after radical cystectomy when using a standardized reporting methodology. Clin Genitourin Cancer. 2013;11:189–97.PubMedCrossRefGoogle Scholar
  159. 159.
    Yuh BE, Nazmy M, Ruel NH, Jankowski JT, Menchaca AR, Torrey RR, et al. Standardized analysis of frequency and severity of complications after robot-assisted radical cystectomy. Eur Urol. 2012;62:806–13.PubMedCrossRefGoogle Scholar
  160. 160.
    Isbarn H, Jeldres C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, et al. A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol. 2009;182:70–7.PubMedCrossRefGoogle Scholar
  161. 161.
    Santos F, Zakaria AS, Kassouf W, Tanguay S, Aprikian A. High hospital and surgeon volume and its impact on overall survival after radical cystectomy among patients with bladder cancer in Quebec. World J Urol. 2015;33:1323–30.PubMedCrossRefGoogle Scholar
  162. 162.
    Wolff I, Brookman-May S, May M. Sex difference in presentation and outcomes of bladder cancer: biological reality or statistical fluke? Curr Opin Urol. 2015;25:418–26.PubMedCrossRefGoogle Scholar
  163. 163.
    Nielsen ME, Shariat SF, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007;51:699–706. discussion 706–8.PubMedCrossRefGoogle Scholar
  164. 164.
    Hollenbeck BK, Miller DC, Taub D, Dunn RL, Underwood W 3rd, Montie JE, et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology. 2004;64:292–7.PubMedCrossRefGoogle Scholar
  165. 165.
    Lin Y, Wang Y, Wu Q, Jin H, Ma G, Liu H, et al. Association between obesity and bladder cancer recurrence: a meta-analysis. Clin Chim Acta. 2018;480:41–6.PubMedCrossRefGoogle Scholar
  166. 166.
    Demark-Wahnefried W, Platz EA, Ligibel JA, Blair CK, Courneya KS, Meyerhardt JA, et al. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomark Prev. 2012;21:1244–59.CrossRefGoogle Scholar
  167. 167.
    Mari A, Kimura S, Foerster B, Abufaraj M, D’Andrea D, Gust KM, et al. A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. Urol Oncol. 2018;36(6):293–305.PubMedCrossRefGoogle Scholar
  168. 168.
    Herrmann E, Stoter E, van Ophoven A, Bierer S, Bolenz C, Hertle L, et al. The prognostic impact of pelvic lymph node metastasis and lymphovascular invasion on bladder cancer. Int J Urol. 2008;15:607–11.PubMedCrossRefGoogle Scholar
  169. 169.
    Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005;23:6533–9.PubMedCrossRefGoogle Scholar
  170. 170.
    Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009;22 (Suppl 2):S96–S118.PubMedCrossRefGoogle Scholar
  171. 171.
    Tamas EF, Nielsen ME, Schoenberg MP, Epstein JI. Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol. 2007;20:828–34.PubMedCrossRefGoogle Scholar
  172. 172.
    Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007;178(6):2302–6. discussion 7.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Hyeong Dong Yuk
    • 1
  1. 1.Seoul National University HospitalSeoulSouth Korea

Personalised recommendations